SAN ANTONIO, Dec. 17 /PRNewswire/ -- Interim results of the Phase II XeNA (Xeloda in NeoAdjuvant) trial suggest that the combination of oral Xeloda(R) (capecitabine) and Taxotere(R) (docetaxel), with ...
First and only approved peginterferon in combination with ribavirin for previously untreated children with chronic hepatitis C addresses unmet medical need KENILWORTH ...
Drug combinations are highly useful for enhanced therapeutics. Understanding of their mechanisms facilitates the discovery of new multicomponent and multi-target therapeutics. This article describes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results